ABCB1 P-glycoprotein biomarker colorectal cancer diarrhea gastrointestinal toxicity irinotecan (CPT-11) mucositis

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 07 04 2020
accepted: 15 06 2020
entrez: 23 7 2020
pubmed: 23 7 2020
medline: 23 7 2020
Statut: epublish

Résumé

Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the

Identifiants

pubmed: 32695000
doi: 10.3389/fphar.2020.00973
pmc: PMC7338599
doi:

Types de publication

Journal Article

Langues

eng

Pagination

973

Informations de copyright

Copyright © 2020 Riera, Artigas-Baleri, Salazar, Sebio, Virgili, Arranz and Páez.

Références

Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
pubmed: 10716719
Pharmacogenomics J. 2007 Feb;7(1):56-65
pubmed: 16788565
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Pharmacogenomics J. 2011 Feb;11(1):61-71
pubmed: 20177420
N Engl J Med. 1995 Nov 2;333(18):1171-5
pubmed: 7565971
Br J Cancer. 2015 Mar 3;112(5):857-65
pubmed: 25611302
Drug Metab Lett. 2007 Jan;1(1):23-30
pubmed: 19356014
Int J Clin Pharmacol Ther. 2016 Mar;54(3):193-9
pubmed: 26857783
J Clin Oncol. 2003 Mar 1;21(5):807-14
pubmed: 12610178
Pharmacogenomics J. 2018 Jan;18(1):35-42
pubmed: 27845419
Br J Cancer. 2019 Jan;120(2):190-195
pubmed: 30585257
Clin Cancer Res. 2003 Aug 15;9(9):3246-53
pubmed: 12960109
J Clin Oncol. 2009 Jun 1;27(16):2604-14
pubmed: 19349540
Toxicol Appl Pharmacol. 2014 Feb 1;274(3):471-9
pubmed: 24380837
Cancer Chemother Pharmacol. 2013 Jun;71(6):1463-72
pubmed: 23543295
Pharmacol Res. 2018 Oct;136:133-139
pubmed: 30213564
Br J Cancer. 2011 Jun 28;105(1):53-7
pubmed: 21654688
Cancer Chemother Pharmacol. 2002 Apr;49(4):336-41
pubmed: 11914914
Cancer. 2007 Jul 1;110(1):138-47
pubmed: 17534875
Br J Clin Pharmacol. 2018 Jun;84(6):1389-1392
pubmed: 29504153
Pharmacogenet Genomics. 2013 Oct;23(10):549-57
pubmed: 24018773
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Pharmacogenetics. 2003 Dec;13(12):741-57
pubmed: 14646693
J Clin Oncol. 2004 Apr 15;22(8):1382-8
pubmed: 15007088
Br J Cancer. 2004 Aug 16;91(4):678-82
pubmed: 15280927
Pharmacogenet Genomics. 2015 Dec;25(12):573-83
pubmed: 26352872
Clin Cancer Res. 2004 Aug 1;10(15):5151-9
pubmed: 15297419
Lung Cancer. 2009 Jan;63(1):115-20
pubmed: 18221820

Auteurs

Pau Riera (P)

Genetics Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Spain.
Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Alícia Artigas-Baleri (A)

Genetics Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Juliana Salazar (J)

Translational Medical Oncology Laboratory, Institut de Recerca Biomèdica Sant Pau, (IIB-Sant Pau), Barcelona, Spain.

Ana Sebio (A)

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Anna C Virgili (AC)

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

María Jesús Arranz (MJ)

Research Laboratory, Fundació Docència i Investigació Mútua Terrassa, Terrassa, Spain.

David Páez (D)

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
U705, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain.

Classifications MeSH